JP2024531477A - Ｐａｒｐ阻害剤としての置換三環式化合物およびその使用 - Google Patents
Ｐａｒｐ阻害剤としての置換三環式化合物およびその使用 Download PDFInfo
- Publication number
- JP2024531477A JP2024531477A JP2024513014A JP2024513014A JP2024531477A JP 2024531477 A JP2024531477 A JP 2024531477A JP 2024513014 A JP2024513014 A JP 2024513014A JP 2024513014 A JP2024513014 A JP 2024513014A JP 2024531477 A JP2024531477 A JP 2024531477A
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- piperazin
- pyridin
- methylcarbamoyl
- quinoxalin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111000443 | 2021-08-27 | ||
| CN202111000443.7 | 2021-08-27 | ||
| CN202111447991.4 | 2021-11-30 | ||
| CN202111447991 | 2021-11-30 | ||
| CN202210274490.9 | 2022-03-18 | ||
| CN202210274490 | 2022-03-18 | ||
| PCT/CN2022/115259 WO2023025307A1 (en) | 2021-08-27 | 2022-08-26 | Substituted tricyclic compounds as parp inhibitors and use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024531477A true JP2024531477A (ja) | 2024-08-29 |
| JPWO2023025307A5 JPWO2023025307A5 (https=) | 2025-08-20 |
| JP2024531477A5 JP2024531477A5 (https=) | 2025-08-20 |
Family
ID=85322483
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024513014A Pending JP2024531477A (ja) | 2021-08-27 | 2022-08-26 | Ｐａｒｐ阻害剤としての置換三環式化合物およびその使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240368169A1 (https=) |
| EP (1) | EP4392425A4 (https=) |
| JP (1) | JP2024531477A (https=) |
| KR (1) | KR20240053612A (https=) |
| CN (1) | CN117980307A (https=) |
| AU (1) | AU2022334408A1 (https=) |
| CA (1) | CA3230491A1 (https=) |
| IL (1) | IL311024A (https=) |
| MX (1) | MX2024002425A (https=) |
| WO (1) | WO2023025307A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230159525A1 (en) | 2021-10-01 | 2023-05-25 | Xinthera, Inc. | Azetidine and pyrrolidine parp1 inhibitors and uses thereof |
| AU2023209820B2 (en) | 2022-01-21 | 2024-10-10 | Xinthera, Inc. | Parp1 inhibitors and uses thereof |
| IL315586A (en) * | 2022-03-11 | 2024-11-01 | Impact Therapeutics Shanghai Inc | Substituted tricyclic compounds as parp inhibitors and the use thereof |
| KR20240161147A (ko) | 2022-03-14 | 2024-11-12 | 슬랩 파마슈티컬스 엘엘씨 | 다중 사이클릭 화합물 |
| FI4497438T3 (fi) | 2022-04-28 | 2025-10-20 | Xinthera Inc | Trisyklisiä parp1:n estäjiä ja niiden käyttötapoja |
| CN119110801A (zh) * | 2022-05-07 | 2024-12-10 | 南京明德新药研发有限公司 | 选择性抑制parp1的氟代喹喔啉酮衍生物 |
| CN115232129B (zh) * | 2022-08-18 | 2023-12-01 | 上海闻耐医药科技有限公司 | 一种parp1选择性抑制剂及其制备方法和用途 |
| CN117263943A (zh) * | 2022-09-09 | 2023-12-22 | 轩竹生物科技股份有限公司 | 聚（adp核糖）聚合酶选择性抑制剂 |
| JP2025538192A (ja) * | 2022-11-10 | 2025-11-26 | 上海海和薬物研究開発股▲ふん▼有限公司 | 縮合三環式ｐａｒｐ１阻害剤、その調製方法、および使用 |
| CN120677162A (zh) * | 2023-06-13 | 2025-09-19 | 中国医药研究开发中心有限公司 | 含氮杂环类化合物及其医药用途 |
| TW202525808A (zh) * | 2023-09-13 | 2025-07-01 | 大陸商上海瑛派藥業有限公司 | 用作ｐａｒｐ１抑制劑的化合物、其用途及包含其之組合物 |
| CN117567473B (zh) * | 2023-11-09 | 2025-07-04 | 中国药科大学 | 一种靶向同源二聚体的抑制剂及其制备方法与应用 |
| AR134686A1 (es) * | 2023-12-13 | 2026-03-04 | Eikon Therapeutics Inc | Síntesis novedosa de compuestos tricíclicos sustituidos |
| CN120923504A (zh) | 2024-05-09 | 2025-11-11 | 上海瑛派药业有限公司 | Parp1抑制剂的晶型及其制备 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3989816A (en) | 1975-06-19 | 1976-11-02 | Nelson Research & Development Company | Vehicle composition containing 1-substituted azacycloheptan-2-ones |
| US4444762A (en) | 1980-04-04 | 1984-04-24 | Nelson Research & Development Company | Vehicle composition containing 1-substituted azacyclopentan-2-ones |
| AUPS137402A0 (en) | 2002-03-26 | 2002-05-09 | Fujisawa Pharmaceutical Co., Ltd. | Novel tricyclic compounds |
| CN101616919B (zh) | 2006-12-28 | 2012-10-10 | 雅培制药有限公司 | 聚（adp核糖）聚合酶抑制剂 |
| CA2716726C (en) | 2008-03-27 | 2017-01-24 | Janssen Pharmaceutica Nv | Tetrahydrophenanthridinones and tetrahydrocyclopentaquinolinones as parp and tubulin polymerization inhibitors |
| KR101779137B1 (ko) * | 2009-01-23 | 2017-09-18 | 다케다 야쿠힌 고교 가부시키가이샤 | 폴리(ａｄｐ-리보스)폴리머라제(ｐａｒｐ) 억제제 |
| ES2604305T3 (es) | 2009-07-14 | 2017-03-06 | Nerviano Medical Sciences S.R.L. | 3-oxo-2,3-dihidro-1H-isoindol-4-carboxamida con inhibición selectiva de PARP-1 |
| EP2459561A1 (en) | 2009-07-30 | 2012-06-06 | Takeda Pharmaceutical Company Limited | Poly (adp-ribose) polymerase (parp) inhibitors |
| WO2013014038A1 (en) | 2011-07-26 | 2013-01-31 | Nerviano Medical Sciences S.R.L. | 3-oxo-2,3-dihydro-1h-indazole-4-carboxamide derivatives as parp-1 inhibitors |
| PH12017502228B1 (en) * | 2015-06-09 | 2022-08-03 | Onconic Therapeutics Inc | Tricyclic derivative compound, method for preparing same, and pharmaceutical composition comprising same |
| GB201800733D0 (en) * | 2018-01-17 | 2018-02-28 | Cambridge Entpr Ltd | Cancer |
| MX2022000711A (es) | 2019-07-19 | 2022-02-23 | Astrazeneca Ab | Inhibidores de parp1. |
| US11795158B2 (en) | 2020-06-25 | 2023-10-24 | Astrazeneca Ab | Chemical compounds |
| CN112028829B (zh) * | 2020-09-25 | 2022-02-15 | 温州大学 | 一种合成菲啶酮类化合物的方法 |
| TW202309025A (zh) * | 2021-04-19 | 2023-03-01 | 美商辛瑟拉股份有限公司 | Parp1抑制劑及其用途 |
| FI4497438T3 (fi) * | 2022-04-28 | 2025-10-20 | Xinthera Inc | Trisyklisiä parp1:n estäjiä ja niiden käyttötapoja |
-
2022
- 2022-08-26 AU AU2022334408A patent/AU2022334408A1/en active Pending
- 2022-08-26 MX MX2024002425A patent/MX2024002425A/es unknown
- 2022-08-26 KR KR1020247010055A patent/KR20240053612A/ko active Pending
- 2022-08-26 CA CA3230491A patent/CA3230491A1/en active Pending
- 2022-08-26 JP JP2024513014A patent/JP2024531477A/ja active Pending
- 2022-08-26 CN CN202280058269.8A patent/CN117980307A/zh active Pending
- 2022-08-26 WO PCT/CN2022/115259 patent/WO2023025307A1/en not_active Ceased
- 2022-08-26 EP EP22860653.9A patent/EP4392425A4/en active Pending
- 2022-08-26 IL IL311024A patent/IL311024A/en unknown
- 2022-08-26 US US18/687,111 patent/US20240368169A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN117980307A (zh) | 2024-05-03 |
| EP4392425A4 (en) | 2025-09-03 |
| KR20240053612A (ko) | 2024-04-24 |
| CA3230491A1 (en) | 2023-03-02 |
| EP4392425A1 (en) | 2024-07-03 |
| WO2023025307A1 (en) | 2023-03-02 |
| US20240368169A1 (en) | 2024-11-07 |
| MX2024002425A (es) | 2024-04-29 |
| AU2022334408A1 (en) | 2024-02-15 |
| IL311024A (en) | 2024-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024531477A (ja) | Ｐａｒｐ阻害剤としての置換三環式化合物およびその使用 | |
| US20250320219A1 (en) | Substituted fused heteroaromatic bicyclic compounds as kinase inhibitors and the use thereof | |
| JP2025508122A (ja) | Ｐａｒｐ阻害剤としての置換三環式化合物およびその使用 | |
| WO2022199652A1 (en) | Five-membered heteroaryl-pyrimidine compounds as usp1 inhibitors and the use thereof | |
| JP2020502065A (ja) | ８，９−ジヒドロイミダゾール［１，２−ａ］ピリミド［５，４−ｅ］ピリミジン−５（６Ｈ）−ケトン類化合物 | |
| CN119661557A (zh) | 作为激酶抑制剂的二取代含氮五元杂芳基化合物及其应用 | |
| WO2022253188A1 (en) | Nitrogen-containing fused heteroaromatic bicyclic compounds as usp1 inhibitors and the use thereof | |
| CN110914277B (zh) | 咪唑并[1,2-b]嘧啶并[4,5-d]哒嗪-5(6H)-酮类化合物及其应用 | |
| JP2020504139A (ja) | キナーゼ阻害剤としての置換された縮合ヘテロアリール化合物及びその用途 | |
| JP2024540921A (ja) | Ｕｓｐ１阻害剤としての置換トリアゾロヘテロアリール化合物及びその応用 | |
| CN116783181B (zh) | 取代的稠合双环类化合物作为parp抑制剂及其应用 | |
| WO2024083237A1 (en) | Substituted heteroaryl bicyclic compounds as usp1 inhibitors and the use thereof | |
| EP4673448A1 (en) | Substituted nitrogen-containing tricyclic compounds as parp inhibitors and the use thereof | |
| HK40104162A (zh) | 取代的三环类化合物作为parp抑制剂及其应用 | |
| HK40115331A (zh) | 作为parp抑制剂的取代的三环类化合物及其应用 | |
| KR20220062003A (ko) | 치환된 이미다조퀴녹살린 화합물 및 이의 용도 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20250407 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20250414 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20250407 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250808 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20250808 |